Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer.

den Braver-Sewradj SP, den Braver MW, Vermeulen NP, Commandeur JN, Richert L, Vos JC.

Toxicol In Vitro. 2016 Jun;33:71-9. doi: 10.1016/j.tiv.2016.02.013. Epub 2016 Feb 26.

PMID:
26921663
2.

Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.

den Braver-Sewradj SP, den Braver MW, Baze A, Decorde J, Fonsi M, Bachellier P, Vermeulen NPE, Commandeur JNM, Richert L, Vos JC.

Eur J Pharm Sci. 2017 Nov 15;109:96-110. doi: 10.1016/j.ejps.2017.07.032. Epub 2017 Aug 1.

PMID:
28778465
3.

A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes.

Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR.

Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12.

PMID:
17627976
4.

Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.

den Braver-Sewradj SP, den Braver MW, van Dijk M, Zhang Y, Dekker SJ, Wijaya L, Vermeulen NPE, Richert L, Commandeur JNM, Vos JC.

Curr Drug Metab. 2018;19(4):370-381. doi: 10.2174/1389200219666180108160046.

PMID:
29318967
5.

Glucuronidation and sulfation of 7-hydroxycoumarin in liver matrices from human, dog, monkey, rat, and mouse.

Wang Q, Jia R, Ye C, Garcia M, Li J, Hidalgo IJ.

In Vitro Cell Dev Biol Anim. 2005 Mar-Apr;41(3-4):97-103.

PMID:
16029080
6.

Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.

Yokoyama Y, Sasaki Y, Terasaki N, Kawataki T, Takekawa K, Iwase Y, Shimizu T, Sanoh S, Ohta S.

Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.

7.

A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations.

Lahoz A, Donato MT, Montero S, Castell JV, Gómez-Lechón MJ.

Rapid Commun Mass Spectrom. 2008;22(2):240-4.

PMID:
18088071
8.

A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes.

Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, Sahi J.

J Pharm Sci. 2012 Oct;101(10):3989-4002. doi: 10.1002/jps.23262. Epub 2012 Jul 17.

PMID:
22806329
10.

Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade.

Sudo M, Nishihara M, Takahashi J, Asahi S.

Drug Metab Dispos. 2017 Jul;45(7):734-736. doi: 10.1124/dmd.117.075234. Epub 2017 Apr 14.

PMID:
28411281
11.

The use of hepatocytes to investigate UDP-glucuronosyltransferases and sulfotransferases.

Fournel-Gigleux S, Coughtrie MW, Ouzzine M, Magdalou J.

Methods Mol Biol. 2010;640:309-26. doi: 10.1007/978-1-60761-688-7_17.

PMID:
20645060
12.

Inter-species comparison of 7-hydroxycoumarin glucuronidation and sulfation in liver S9 fractions.

Wang Q, Ye C, Jia R, Owen AJ, Hidalgo IJ, Li J.

In Vitro Cell Dev Biol Anim. 2006 Jan-Feb;42(1-2):8-12.

PMID:
16618213
13.

Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes.

Cho YY, Jeong HU, Kim JH, Lee HS.

Drug Des Devel Ther. 2014 Nov 3;8:2137-45. doi: 10.2147/DDDT.S72305. eCollection 2014.

14.

In vitro phase II metabolism of xanthohumol by human UDP-glucuronosyltransferases and sulfotransferases.

Ruefer CE, Gerhäuser C, Frank N, Becker H, Kulling SE.

Mol Nutr Food Res. 2005 Sep;49(9):851-6.

PMID:
16092069
15.

Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ.

Drug Metab Dispos. 2013 Mar;41(3):554-61. doi: 10.1124/dmd.112.048439. Epub 2012 Dec 7.

16.

Protective effect of hyperoside against acetaminophen (APAP) induced liver injury through enhancement of APAP clearance.

Xie W, Jiang Z, Wang J, Zhang X, Melzig MF.

Chem Biol Interact. 2016 Feb 25;246:11-9. doi: 10.1016/j.cbi.2016.01.004. Epub 2016 Jan 6.

PMID:
26772156
17.

Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes.

Jinno N, Tagashira M, Tsurui K, Yamada S.

Xenobiotica. 2014 Aug;44(8):677-86. doi: 10.3109/00498254.2014.894219. Epub 2014 Feb 27.

PMID:
24575896
18.

Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.

Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S.

Chem Res Toxicol. 2006 May;19(5):701-9.

PMID:
16696573
20.

Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.

Westerink WM, Schoonen WG.

Toxicol In Vitro. 2007 Dec;21(8):1592-602. Epub 2007 Jul 18.

PMID:
17716855

Supplemental Content

Support Center